Nature Communications: Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1 (VIDEO)
Caption
AI Designs a Novel PROTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end approach to new modality drug discovery.
A Superior Dual-Action Mechanism: The novel PROTAC, D16-M1P2, employs a powerful dual-action mechanism that simultaneously degrades and inhibits the cancer-driving PKMYT1 protein, resulting in a more potent, selective, and durable therapeutic effect than traditional inhibitors.
Strong Preclinical Results Move Therapy Forward: The AI-designed PROTAC delivered potent anti-tumor activity with high selectivity and favorable oral bioavailability in preclinical studies, and has now advanced to the pre-candidate validation stage.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content